Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat ...

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.

The New York Times reports that the tentative $7.4 billion agreement with 15 states would also require those states to set aside as much as $800 million in what amounts to a legal defense fund for the ...

A surge in respiratory illness is typical for this time of year, and the simultaneous outbreak of highly contagious norovirus is piling on to the public health risk. Commonly known as stomach flu, ...

Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

While norovirus is not generally life-threatening, the CDC reports that it causes 900 deaths and 109,000 hospitalizations on ...

Unless they’re covering me in a cloud of norovirus particles. When the violent expelling of liquid starts somewhere other ...

Brooklyn Investment Group reduced its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 34.8% during the 4th quarter, ...

COVID-19, influenza, respiratory syncytial virus (RSV), and norovirus — have spread nationwide in especially high numbers ...